Q-omics provides the consensus-scored INCENP profile across patient tissues and cancer cell-line models. INCENP expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, INCENP is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, INCENP protein abundance shows 21,617 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where INCENP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INCENP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INCENP survival associations across molecular data types. INCENP RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INCENP RNA expression–survival associations across cancer types. High INCENP expression shows unfavorable associations in MESO, KICH, ACC, PAAD and LIHC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for INCENP RNA expression.
This table summarizes INCENP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for INCENP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INCENP shows higher tumor expression in BLCA, COAD, HNSC, LIHC, LUAD and KIRC. The BLCA box plot shows higher INCENP RNA expression in tumor versus normal tissue (log2 FC = +1.841, t-test p < 0.001).
This table shows molecular features associated with INCENP in patient tissues and cancer cell lines. In patient samples, INCENP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, INCENP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
